Shanghai Bio-heart Biological Technology Co., Ltd. (“BIOHEART-B”) will hold its 2025 annual general meeting on 26 June 2026 in Shanghai. The register of H-shareholders closes from 15–26 June; shareholders recorded on 26 June are eligible to vote.

Key resolutions put to shareholders include:

1. 2025 performance review • Board and Audit Committee work reports and the audited 2025 consolidated financial statements will be tabled for approval. • The Board proposes no final dividend for FY2025, citing operating results, financial position and future development plans.

2. Board composition and auditor re-appointment • Six incumbent directors—Philip Li Wang, Yunqing Wang, Peili Wang, and independent non-executive directors Yiqing Chen, Xubo Lu and Yifei Jiang—are nominated for re-election to the third Board. • Ernst & Young Hua Ming LLP (domestic) and Ernst & Young (international) are proposed for re-appointment as 2026 auditors with estimated combined fees of RMB 0.80–1.50 million.

3. Corporate governance overhaul • Shareholders will vote on abolishing the Board of Supervisors and adopting amended Articles of Association that transfer supervisory functions to the Audit Committee. • Consequential revisions to the Board and shareholders’ meeting procedural rules are proposed.

4. Capital management authorities • The Board seeks a 12-month general mandate to issue, sell or transfer treasury shares up to 20% of each of the Company’s issued H shares and unlisted foreign shares, subject to regulatory approvals.

All AGM resolutions will be decided by poll. Proxies must be lodged no later than 14:00 on 25 June 2026.